BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38165547)

  • 1. CCT2 prevented β-catenin proteasomal degradation to sustain cancer stem cell traits and promote tumor progression in epithelial ovarian cancer.
    Chen J; Hu Q; Zhou C; Jin D
    Mol Biol Rep; 2024 Jan; 51(1):54. PubMed ID: 38165547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway.
    Zhuang XH; Liu Y; Li JL
    Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31337688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway.
    Zhang Y; Dun Y; Zhou S; Huang XH
    Biomed Pharmacother; 2017 Dec; 96():1216-1221. PubMed ID: 29239819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.
    Cao P; Zhao S; Sun Z; Jiang N; Shang Y; Wang Y; Gu J; Li S
    Exp Cell Res; 2018 Oct; 371(1):214-221. PubMed ID: 30118697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis.
    Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X
    Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY75 Ablation Mediates Mesenchymal-Epithelial Transition (MET) in Epithelial Ovarian Cancer (EOC) Cells Associated with DNA Methylation Alterations and Suppression of the Wnt/β-Catenin Pathway.
    Mehdi S; Bachvarova M; Scott-Boyer MP; Droit A; Bachvarov D
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32156068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT1-Induced Upregulation lncRNA LINC00958 Accelerates the Epithelial Ovarian Cancer Tumorigenesis by Regulating Wnt/
    Xie M; Fu Q; Wang PP; Cui YL
    Dis Markers; 2021; 2021():1405045. PubMed ID: 34790276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway.
    Pei L; Zhao F; Zhang Y
    Apoptosis; 2024 Feb; 29(1-2):210-228. PubMed ID: 38087046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
    Duan H; Yan Z; Chen W; Wu Y; Han J; Guo H; Qiao J
    Gynecol Oncol; 2017 Nov; 147(2):408-417. PubMed ID: 28851501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GOLPH3 induces epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in epithelial ovarian cancer.
    Sun J; Yang X; Zhang R; Liu S; Gan X; Xi X; Zhang Z; Feng Y; Sun Y
    Cancer Med; 2017 Apr; 6(4):834-844. PubMed ID: 28332316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine-Rich Intestinal Protein 1 Served as an Epithelial Ovarian Cancer Marker via Promoting Wnt/
    Liu Y; Li W; Luo J; Wu Y; Xu Y; Chen T; Zhang W; Fu F
    Dis Markers; 2021; 2021():3566749. PubMed ID: 34413913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces β-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma.
    Burkhalter RJ; Westfall SD; Liu Y; Stack MS
    J Biol Chem; 2015 Sep; 290(36):22143-54. PubMed ID: 26175151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
    Ma X; Wang B; Wang X; Luo Y; Fan W
    PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNF144A suppresses ovarian cancer stem cell properties and tumor progression through regulation of LIN28B degradation via the ubiquitin-proteasome pathway.
    Li Y; Wang J; Wang F; Chen W; Gao C; Wang J
    Cell Biol Toxicol; 2022 Oct; 38(5):809-824. PubMed ID: 33978933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ-CCT2 Activates Wnt/β-catenin Signaling to Facilitate Hepatoblastoma Development by Stabilizing PTBP1 mRNA.
    Zhu Q; Hu Y; Jiang W; Ou ZL; Yao YB; Zai HY
    Cell Mol Gastroenterol Hepatol; 2024; 17(2):175-197. PubMed ID: 37866478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer.
    Malgundkar SH; Burney I; Al Moundhri M; Al Kalbani M; Lakhtakia R; Okamoto A; Tamimi Y
    BMC Cancer; 2020 May; 20(1):374. PubMed ID: 32366234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab.
    Shen G; Gao Q; Liu F; Zhang Y; Dai M; Zhao T; Cheng M; Xu T; Jin P; Yin W; Huang D; Weng H; Chen W; Ren H; Mu X; Wu X; Hu S
    Biochem Biophys Res Commun; 2020 Jun; 526(3):685-691. PubMed ID: 32248976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP25 promotes hepatocellular carcinoma progression by interacting with TRIM21 via the Wnt/β-catenin signaling pathway.
    Liu Y; Ma J; Lu S; He P; Dong W
    Chin Med J (Engl); 2023 Sep; 136(18):2229-2242. PubMed ID: 37439386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. circFBXO7/miR-96-5p/MTSS1 axis is an important regulator in the Wnt signaling pathway in ovarian cancer.
    Wu M; Qiu Q; Zhou Q; Li J; Yang J; Zheng C; Luo A; Li X; Zhang H; Cheng X; Lu W; Liu P; Lu B; Lu Y
    Mol Cancer; 2022 Jun; 21(1):137. PubMed ID: 35768865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.